Outcomes for anticoagulation vs discontinuation during thrombocytopenia
| . | Continuation (n = 132) . | Discontinuation (n = 72) . | Odds ratio . | P . |
|---|---|---|---|---|
| Primary outcomes, n (%) | ||||
| VTE recurrence by 30 d | 2 (1.5) | 1 (1.4) | 1.27 | .85* |
| Major bleeding (grade 3-4) by 30 d | 5 (3.8) | 3 (4.2) | 0.91 | .89† |
| Secondary outcomes | ||||
| Overall bleeding (grade 2-4) by 30 d, n (%) | 51 (39) | 22 (31) | 1.43 | .25† |
| Overall mortality by 30 d, n (%) | 2 (2) | 3 (4) | 0.35 | .26† |
| Number of platelet transfused | 9 (6-13) | 4 (2-6) | NA | <.01‡ |
| Number of RBC transfused | 4 (2-5) | 4 (2-6) | NA | .53‡ |
| Time to platelet >50 × 103/μL | 14 (12-17) | 15 (13-17) | NA | .61‡ |
| Time to neutrophil >500 cells/μL | 14 (12-16) | 14 (12-15) | NA | .49‡ |
| . | Continuation (n = 132) . | Discontinuation (n = 72) . | Odds ratio . | P . |
|---|---|---|---|---|
| Primary outcomes, n (%) | ||||
| VTE recurrence by 30 d | 2 (1.5) | 1 (1.4) | 1.27 | .85* |
| Major bleeding (grade 3-4) by 30 d | 5 (3.8) | 3 (4.2) | 0.91 | .89† |
| Secondary outcomes | ||||
| Overall bleeding (grade 2-4) by 30 d, n (%) | 51 (39) | 22 (31) | 1.43 | .25† |
| Overall mortality by 30 d, n (%) | 2 (2) | 3 (4) | 0.35 | .26† |
| Number of platelet transfused | 9 (6-13) | 4 (2-6) | NA | <.01‡ |
| Number of RBC transfused | 4 (2-5) | 4 (2-6) | NA | .53‡ |
| Time to platelet >50 × 103/μL | 14 (12-17) | 15 (13-17) | NA | .61‡ |
| Time to neutrophil >500 cells/μL | 14 (12-16) | 14 (12-15) | NA | .49‡ |
NA, not applicable.
Logistic regression model was used to test for association between VTE recurrence at 30 d and the 2 cohorts (adjusted by index VTE acuity).
Logistic regression model was used to test for association between bleeding or mortality at 30 d and the 2 cohorts (unadjusted).
Linear regression model was used to test for association between transfusion or engraftment time and the 2 cohorts (unadjusted).